network member

Knight Cancer Institute at Oregon Health & Science University

Portland, OR
Knight Cancer Institute at Oregon Health & Science University

About Network Member

The OHSU Knight Cancer Institute, known as one of the pioneers in personalized cancer medicine, is an international leader in research and cancer treatment. The institute’s director, Brian Druker, MD, helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. Driven by its mission to end cancer as we know it, the institute is building upon its expertise in targeted treatments to advance the early detection of cancer when the disease is most treatable. The OHSU Knight Cancer Institute is the only National Cancer Institute Comprehensive Cancer Center between Sacramento and Seattle – an honor earned only by the nation’s top cancer centers. The Knight Cancer Institute is also the headquarters for the NCI’s SWOG collaborative, a cancer research cooperative group that designs and conducts multidisciplinary clinical trials to improve the practice of medicine for preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. Website: ohsu.edu/knight-cancer-institute
Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
Cancer areas:Prostate
City of Hope
Froedtert & the Medical College of Wisconsin
Knight Cancer Institute at Oregon Health & Science University
University of Michigan Rogel Cancer Center
Winship Cancer Institute of Emory University
Enrollment Closed

HCRN-GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Cancer areas:Colorectal
Cleveland Clinic Cancer Center
Knight Cancer Institute at Oregon Health & Science University
Rutgers Cancer Institute of New Jersey
Sylvester Comprehensive Cancer Center at the University of Miami
The Ohio State University
University of Kansas Medical Center
Enrollment Closed

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
Cancer areas:Bladder
City of Hope
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Knight Cancer Institute at Oregon Health & Science University
Penn Medicine Abramson Cancer Center
University of Wisconsin Carbone Cancer Center
USC Norris Comprehensive Cancer Center